Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Which Is More Suitable For Aggressive Investors Index Fund Vs Target Date weighs volatility, potential upside, and suitability for growth-focused plans.
28,574 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
As Cognyte readies its Q1 2027 earnings report, investors want clarity on growth, margins, and cash flow. This guide ...
A major insider purchase by BORR's Executive Director has investors buzzing. This article breaks down what the move c...
Investors are racing to price in the first real revenue opportunities from quantum tech as a new federal funding push...
Bitcoin has fallen about 50% from its October peak as global liquidity rose. Some analysts say bitcoin dumped when gl...
A major market moment is shaping up as Dan Ives weighs in on SpaceX’s potential public debut. This article breaks dow...
A comeback that ends in minutes isn't just sports news—it’s a blueprint for financial planning. Learn how to shield y...
A political push for a different rate path could reshape markets. This article breaks down what a president donald tr...
Emerging market small caps are posting growing trailing dividends despite volatile quarterly payments, helping them b...
A potential revival of 100% bonus depreciation in 2026 could dramatically change real estate investing. This guide la...
A fresh look at an internal code snippet raises questions about Anthropic’s plans for Fable 5, potentially tying week...